A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

A researcher found that using Anthropic’s Claude Opus 4.7, he could break into the website of Front Gate—used by every ...

As Microsoft phases out older Exchange Server versions, IT leaders are facing new decisions about how to stay compliant and cost-efficient. Understanding the current licensing landscape for Windows ...

Happy new year! Welcome to 2025, and congratulations for living through yet another complete rotation around the giant firey gas ball we call the sun. The start of a new year is as good a time as any ...

The WSJ/College Pulse 2025 Best Colleges in the U.S. ranking rates the top 500 universities in the country. The ranking was developed and executed in collaboration with our research partners College ...

This has been a year of elections, resistance, and conflict, testing the integrity of democratic institutions and the principles of international human rights and humanitarian law. Whether in response ...

The 247Sports Composite is a proprietary algorithm that compiles rankings and ratings listed in the public domain by the major media recruiting services, creating the ...

Python’s lead narrows again, C holds the runner-up spot, C++ returns to third, and SQL climbs back above R in June’s top 10 rankings update. June’s TIOBE Index has the feel of a rematch month. The top ...

Sept 2 Last Day to add a course. And, Last Day to drop a course without paying tuition & fees. Sept 2 Last Day to a Submit Graduate & Undergraduate Application for Degree Sept 3 – Oct 8 Extended Drop ...

A 10-Week Course on Advanced Excel for Business Analytics in 2026,' offers a comprehensive pathway to mastering Excel for ...

Katelyn is a reporter with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content ...

Talquetamab, a bispecific antibody targeting GPRC5D and CD3, has led to durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma in phase 1–2 trials, with a ...